بيتا
رادار التجارب AI
دراسة واحدة تطابق معايير الفلتر
عرض البطاقة

Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps. المرحلة الرابعة ٧٠ عشوائية

غير معروف
تفاصيل التجربة السريرية متاحة بشكل أساسي باللغة الإنجليزية. ومع ذلك، يمكن لـ رادار التجارب AI مساعدتك؛ ما عليك سوى النقر على «وصف الدراسة» لعرض ومناقشة معلومات الدراسة باللغة التي اخترتها.
التجربة السريرية NCT02685449 مصممة لدراسة علاج لـالسكري النوع 1. إنها دراسة تدخُّلية من المرحلة الرابعة وهي غير معروف. بدأت في ٢٢ ربيع الآخر ١٤٣٧ هـ مع خطة لتجنيد ٧٠ مشاركًا. تقودها جامعة وارسو الطبية، ومن المتوقع اكتمالها بحلول ١٩ ذو القعدة ١٤٣٩ هـ. تم تحديث البيانات الأخيرة من ClinicalTrials.gov في ٢٤ شوال ١٤٣٧ هـ.
الملخص
This is a randomized, cross-over study. The aim of this study is to compare the post-prandial glycaemic variability after pure protein meal following with an administration of square-wave bolus of meal-insulin or without any meal-insulin bolus on the other day.

Prolonged post-prandial glycaemic variability will be identified using the self-monitoring of blood glucose (10-point curve) and CGMS.

وصف مفصل
The square-wave bolus (for meals rich in fat and/or protein) is evenly delivered over several hours as programmed by the patient. The required insulin dose will be calculated based on patient's insulin-exchange ratio. Pure protein meal will be given 3 hours after a first breakfast.

To provide the minimal impact of the previous breakfast, all patients will receive up to 120 kcal of carbohydrates and <100 kcal from p...

عرض المزيد
العنوان الرسمي

Insulin Requirement for Pure- Protein Meal in Children With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion - a Cross-over, Randomized Trial.

الحالات الطبية
السكري النوع 1
معرّفات دراسة أخرى
  • Białko_5h
NCT معرّف
تاريخ البدء (فعلي)
2016-02
آخر تحديث مُنشور
2016-07-29
تاريخ الاكتمال (المقدر)
2018-08
عدد المشاركين المخطط لهم
٧٠
نوع الدراسة
تدخُّلية
المرحلة
المرحلة الرابعة
الحالة
غير معروف
الكلمات الرئيسية
diabetes type 1
insulin pump
prandial insulin requirement
pure protein meal
high protein meal
square bolus
square-wave bolus
insulin bolus
dietary protein
الغرض الأساسي
العلاج
طريقة توزيع المشاركين
عشوائي
نموذج التدخل
تصميم متقاطع
التعمية
مزدوج
مجموعات/التدخلات
مجموعة المشاركين/الذراعالتدخل/العلاج
مقارن بالدواء الوهميgroup A
On the first study day, insulin bolus was not given before a standardized pure protein meal. On the second day, pre-breakfast insulin was given as a square-wave bolus before the same standardized pure protein meal. The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by th...عرض المزيد
Insulin glulisine
A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
Insulin aspart
A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Insulin lispro
A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
مقارن نشطgroup B
On the first study day, pre-breakfast insulin was given as a square-wave bolus before a standardized pure protein meal. On the second day, insulin bolus was not given before the same standardized pure protein meal. The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by th...عرض المزيد
Insulin glulisine
A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
Insulin aspart
A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Insulin lispro
A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
النتيجة الرئيسية
مقياس النتيجةوصف القياسالإطار الزمني
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
30 minutes after the meal
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
60 minutes after the meal
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
90 minutes after the meal
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
120 minutes after the meal
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
150 minutes after the meal
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
180 minutes after the meal
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
210 minutes after the meal
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
240 minutes after the meal
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
270 minutes after the meal
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
300 minutes after the meal
النتيجة الثانوية
مقياس النتيجةوصف القياسالإطار الزمني
Hypoglycemia episodes
Hypoglycemia defined as a plasma glucose concentration below 65 mg/dl with or without symptoms
5-hour study period
Glucose Area Under the Curve (AUC)
Measurements based on CGMS
5-hour study period
Mean amplitude of glycemic excursion
measurements based on SMBG
5-hour study period
The difference between the maximum and baseline glucose level
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
5-hour study period
معايير الأهلية

الأعمار المؤهلة للدراسة
طفل, بالغ
العمر الأدنى للدراسة
10 Years
الجنس المؤهل
الكل
  • duration of type 1 diabetes longer than 12 months
  • insulin pump therapy longer than 3 months
  • written informed consent by patients and parents
  • insulin requirement more than 0,5 units/kg/day

  • diabetes related complications (e.g. nephropathy)
  • chronic kidney diseases
  • any disease judged by the investigator to affect the trial
  • withdrawal of consent to participate in the study
Medical University of Warsaw logoجامعة وارسو الطبية79 دراسات نشطة للاستكشاف
جهة اتصال مركزية للدراسة
جهة اتصال: Kamila Indulska, 48223179421
جهة اتصال: Katarzyna Dżygało, 48223179538, [email protected]
1 مواقع الدراسة في 1 بلدان
Medical University, Warsaw, 02- 091, Poland
Agnieszka Szypowska, MD, PhD, جهة اتصال, +48223179421
Kamila Indulska, محقق فرعي
Katarzyna Dżygało, المحقق الرئيسي
يقبل مشاركين